US Secondary Hyperparathyroidism Treatment (SHPT) Market Size, Share, Growth Analysis, By Drug Analysis(hospital & retail pharmacies, online channel) - Industry Forecast 2024-2031

US Secondary Hyperparathyroidism Treatment (SHPT) Market size was valued at USD 4.59 billion in 2019 and is poised to grow from USD 5 billion in 2023 to USD 9.97 billion by 2031, growing at a CAGR of 9% in the forecast period (2024-2031).

Secondary hyperparathyroidism is characterized by the sustained rises in levels of biochemical indicators of mineral metabolism that lead to the release of excessive amounts of parathyroid hormone (SHPT). It affects persons with chronic kidney disease (CKD) and those who need renal replacement therapy. The Centers for Disease Control and Prevention (CDC) currently projects that 37 million Americans, or about 15% of adult Americans, have CKD. Furthermore, CKD is reported to be more prevalent in those 65 years of age and older than in those 45 to 64 years of age. Rising patient numbers are correlated with rising treatment costs for secondary hyperparathyroidism.

Although medications are frequently provided for SHPT, surgery is advised in difficult cases when the thyroid glands release excessive amounts of PTH. Although surgical procedures have demonstrated improved treatment accuracy, they are less preferred due to their expensive cost and the market's accessibility to efficient medications. The U.S. Medicare national insurance programme covers medications for SHPT. Medication for the treatment of SHPT was just added to the Part B package of Medicare Insurance in January 2018. In the United States, there are numerous nonprofit organizations that support patients who are uninsured or have inadequate insurance, significantly lowering the cost of SHPT treatment for everyone. Despite the fact that the government provides health insurance through public programmes, people still have significant out-of-pocket costs.

US Secondary Hyperparathyroidism Treatment (SHPT) Market is poised to grow at a sustainable CAGR for the next forecast period.